Insight Venture Associates X, Ltd

Insight Holdings Group, LLC (10% Owner) sells 426,171 shares for $38,446,957.43 via scheduled 10b5-1 plan at HNGE

Insight Holdings Group, LLC executed 12 separate sales totaling 426,171 shares for $38,446,957.43 on July 7–9, 2026, at prices ranging from $90.17 to $91.00—all within 1.3% of the 52-week high of $91.07. The transaction was executed under a pre-arranged 10b5-1 trading plan, meaning it was scheduled rather than discretionary. Although the non-derivative holdings were fully liquidated through these sales, the insider retains 12,212,817 shares in derivative securities across eight ownership vehicles, so the overall position remains substantial. The timing of this activity near the 52-week high, combined with HNGE's 43.2% rise over the past 30 days and 153.9% rise over 90 days, places these sales in a context of significant recent upward price momentum.

Insight Holdings Group sells 1,466,667 shares of HNGE across 20 transactions for $121,489,333.19 at blended avg $82.83 under 10b5-1 plan

Insight Holdings Group, LLC executed 20 separate sales totaling 1,466,667 shares for $121,489,333.19 at a blended average price of $82.83, conducted under a pre-arranged 10b5-1 trading plan and therefore scheduled rather than discretionary. The sales occurred with the stock trading near its 52-week high of $84.62, reflecting a 30-day price appreciation of +45.0% and a 90-day price appreciation of +111.3% in the period leading up to the trade. Despite the reduction in non-derivative Table I shares to zero, Insight Holdings retains 6,441,830 shares expressed through four derivative (Class B Common Stock) holdings in Table II, meaning its overall position in HNGE remains substantial. Hinge Health reported quarterly revenue of $182.3M with annual revenue growth of +50.6%, though the company carried a negative full-year net income over its most recent fiscal year.

Insight Holdings Group LLC sold 530,982 shares for $38,137,010.65 via 12 transactions on 2026-06-25 under pre-arranged 10b5-1 plan

Insight Holdings Group, LLC, a 10% owner, executed 12 separate sales totaling 530,982 shares for $38,137,010.65 on 2026-06-25 at blended average price of $71.82, eliminating its non-derivative holdings. This transaction is part of a pre-arranged 10b5-1 trading plan, making it scheduled rather than discretionary. The insider retains Class B Common Stock derivative holdings through multiple ownership vehicles. The company's most recent quarter showed revenue of $182,307,000.00 and net income of $35,128,000.00, with annual revenue growth of +50.6%, though the company was unprofitable over its most recent full fiscal year. The current stock price of $81.48 sits 3.7% below the 52-week high of $84.62, suggesting the transaction occurred at a discount to recent peak valuations.

Insight Holdings Group (10% owner) liquidates entire 142.3K-share HNGE position for $10.2M via 10b5-1 plan

Insight Holdings Group filed a Form 4 on 2026-06-24 documenting two separate sales totaling 142,311 shares at $71.67, reducing its holdings from 142.3K shares to 0 shares (a -100.0% reduction). The transaction was executed under a pre-arranged 10b5-1 trading plan, indicating scheduled execution rather than discretionary timing. While the company shows strong recent momentum—30-day change +27.7%, 90-day change +75.6%—and posted revenue of $182.3M with net income of $35.1M in the latest quarter alongside 50.6% annual revenue growth, Insight Holdings' prior trades at HNGE show a mixed pattern, including four separate sales on 2025-12-01 that experienced subsequent 90-day declines of -10.5%. The complete exit is significant given the 10% ownership stake, though the scheduled nature of the 10b5-1 plan removes timing as an interpretive variable.

Insight Holdings Group, LLC sells 727,793 shares of HNGE for $51,634,252.32 under 10b5-1 plan; retains 26,497,370 derivative shares.

Insight Holdings Group, LLC, a 10% owner, executed 18 separate sales totaling 727,793 shares for $51,634,252.32 across three trading dates (June 22–24, 2026) at blended average price of $70.95. The transaction is part of a pre-arranged 10b5-1 trading plan, meaning it is scheduled rather than discretionary. While the non-derivative holding reaches 0 shares post-transaction, the insider retains substantial derivative holdings across 12 ownership vehicles totaling 26,497,370 shares of Class B Common Stock, so the overall position remains material. The stock currently trades at $70.56, near its 52-week high of $72.39, and has risen 27.7% over 30 days and 75.6% over 90 days. HNGE shows strong fundamentals with revenue of $182,307,000.00 and net income of $35,128,000.00 in the latest quarter, alongside annual revenue growth of +50.6%, though the company was unprofitable over its most recent full fiscal year.

Insight Holdings Group (10% owner) sells 65,581 shares at $70.36 via 4 scheduled transactions totaling $4.6M

Insight Holdings Group executed 4 separate sales totaling 65,581 shares for $4,614,252.93 at $70.36 on 2026-06-16, eliminating non-derivative holdings under a pre-arranged 10b5-1 trading plan. The company reported strong fundamentals with revenue of $182,307,000.00 and net income of $35,128,000.00 in the latest quarter, plus annual revenue growth of +50.6%, yet was unprofitable over its most recent full fiscal year. The sale occurred near the 52-week high ($70.72), with the stock at $69.42 currently. The insider's prior sales at HNGE on 2025-12-01 showed 30d returns of -2.7% and 90d returns of -10.5%, while an earlier 2025-05-23 sale posted 90d gains of +75.0%, indicating inconsistent timing outcomes at this ticker. As a scheduled trade under 10b5-1 rules, this represents pre-planned capital allocation rather than discretionary market timing.

10% Owner Insight Holdings divests 1,654,440 shares ($79.0M) at $47.76; post-sale holdings near zero per derivative conversion.

Insight Holdings Group, LLC, a 10% owner of Hinge Health, executed 4 separate sales on 2025-12-01 totaling 1,654,440 shares (1.65M shares) for $79,016,054.40 ($79.0M) at a blended average price of $47.76. The filing flags a derivative-conversion transaction, meaning the shareholder's true residual position is held in derivative securities (Table II), not reflected in the Table I share count—so this should not be characterized as a complete liquidation. The current stock price is $46.02, down 8.6% over 30 days and 17.8% over 90 days, trading 24.0% below its 52-week high of $60.55. Across the insider's cross-ticker track record, prior sells have averaged -5.1% 30-day return and -13.3% 90-day return with a 93.33% well-timed rate, indicating a historical tendency to exit before declines. At the same ticker (HNGE), the insider's single prior sell on 2025-05-23 turned out poorly timed (90d return +75.0%, meaning the stock rose after the sale). The company's fundamentals show revenue of $154,211,000.00 in the latest quarter against a net loss of $1,844,000.00, reflecting ongoing profitability pressure.